Search bioRxiv⌕ Search

Biology subjects

Sanchez Martinez, D.

Publications and source records attributed to Sanchez Martinez, D..

2 recordsLinked to original sources

CellPie: a fast spatial transcriptomics topic discovery method via joint factorization of gene expression and imaging data

Spatially resolved transcriptomics has enabled the study of expression of genes within tissues while retaining their spatial identity. Most spatial transcriptomics technologies generate a matched histopathological image as part of the standard pipeline, providing morphological information that can complement the transcriptomics data. Here we present CellPie, a fast, unsupervised factor discovery method, based on joint non-negative matrix factorisation of spatial RNA transcripts and histological image features.CellPie employs the accelerated hierarchical least squares method to significantly reduce the computational time, enabling efficient application to high-dimensional spatial transcriptomics datasets. We assessed CellPie on two different human cancer types and spatial resolutions, showing an improved performance against published factorisation methods. Additionally, we applied CellPie to a highly resolved Visium HD dataset, demonstrating its high computational efficiency compared to standard non-negative matrix factorisation and other existing methods. Availabilityhttps://github.com/ManchesterBioinference/CellPie

bioinformatics↗

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in Acute Myeloid Leukemia

Chimeric Antigen Receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory (r/r) hematological tumors, showing impressive complete remission rates in B-cell malignancies. However, around 50% of the patients relapse before 1-year post-treatment. T-cell "fitness" is critical to prolong the persistence and activity of the adoptively transferred product. Allogeneic T cells from healthy donors are less dysfunctional or exhausted than autologous patient-derived T cells, enabling a very attractive and cost-effective "off-the-shelf" therapy option. In this context, Delta One T cells (DOTs), a recently described cellular product based on MHC/HLA-independent V{delta}1+ {gamma}{delta} T cells generated from the peripheral blood of healthy donors, represent a robust platform of allogeneic effector T cells. Here we generated and pre-clinically validated 4-1BB-based CAR-DOTs directed against the IL-3 chain receptor (CD123), a target antigen widely expressed on acute myeloid leukemia (AML) blasts. CD123CAR-DOTs showed vigorous, superior to control DOTs, cytotoxicity against AML cell lines and primary samples both in vitro and in vivo. Continuous administration of IL-15 supported the long-term persistence of a single-dose CD123CAR-DOTs in patient-derived xenograft models, sustaining their anti-leukemic efficacy as demonstrated in a re-challenge assay in vivo. Our results provide proof-of-concept for an allogeneic next-generation therapy based on CD123CAR-DOTs for r/r AML patients. KEY POINTS- CD123CAR-DOTs exert specific and robust cytotoxicity in vitro and anti-leukemic activity in vivo against AML cell lines and primary cells. - CD123CAR-DOTs show IL-15-dependent long-term persistence in vivo and vigorous anti-leukemic activity upon re-challenge.

immunology↗